24.85
+0.05
+(0.20%)
At close: 1:33:00 PM GMT+8
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
34,072.00
25,847.00
23,647.00
38,899.00
21,106.00
Cost of Revenue
194,582.00
189,842.00
170,909.00
158,269.00
159,999.00
Gross Profit
-160,510.00
-163,995.00
-147,262.00
-119,370.00
-138,893.00
Operating Expense
185,456.00
156,473.00
170,818.00
174,612.00
101,670.00
Operating Income
-345,966.00
-320,468.00
-318,080.00
-293,982.00
-240,563.00
Net Non Operating Interest Income Expense
-27,784.00
-29,169.00
-21,111.00
-18,692.00
-16,089.00
Pretax Income
-361,707.00
-337,987.00
-327,877.00
-301,756.00
-250,370.00
Net Income Common Stockholders
-361,707.00
-337,987.00
-327,877.00
-301,756.00
-250,370.00
Diluted NI Available to Com Stockholders
-361,707.00
-337,987.00
-327,877.00
-301,756.00
-250,370.00
Basic EPS
-2.68
-2.81
-2.82
-2.89
-2.44
Diluted EPS
-2.68
-2.81
-2.82
-2.89
-2.44
Basic Average Shares
135,667.60
120,462.00
116,133.00
104,402.42
103,514.73
Diluted Average Shares
135,667.60
120,462.00
116,133.00
104,402.42
103,514.73
Total Expenses
380,038.00
346,315.00
341,727.00
332,881.00
261,669.00
Net Income from Continuing & Discontinued Operation
-361,707.00
-337,987.00
-327,877.00
-301,756.00
-250,370.00
Normalized Income
-361,707.00
-337,987.00
-327,877.00
-301,756.00
-250,370.00
Interest Income
6,353.00
4,422.00
1,929.00
848.00
723.00
Interest Expense
34,137.00
33,591.00
23,040.00
19,540.00
16,812.00
Net Interest Income
-27,784.00
-29,169.00
-21,111.00
-18,692.00
-16,089.00
EBIT
-327,570.00
-304,396.00
-304,837.00
-282,216.00
-233,558.00
EBITDA
-241,036.00
-219,585.00
-219,482.00
-196,920.00
-148,612.00
Reconciled Cost of Revenue
194,582.00
189,842.00
170,909.00
158,269.00
159,999.00
Reconciled Depreciation
86,534.00
84,811.00
85,355.00
85,296.00
84,946.00
Net Income from Continuing Operation Net Minority Interest
-361,707.00
-337,987.00
-327,877.00
-301,756.00
-250,370.00
Normalized EBITDA
-241,036.00
-219,585.00
-219,482.00
-196,920.00
-148,612.00
12/31/2020 - 7/15/2014
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
4168.TWO GlycoNex Incorporation
24.00
0.00%
4131.TWO NeoCore Technology Co., Ltd.
31.00
0.00%
4728.TWO Sunmax Biotechnology Co., Ltd.
275.00
+0.18%
4130.TWO Genovate Biotechnology Co., Ltd.
25.30
+1.81%
4726.TWO Mycenax Biotech Inc.
40.25
0.00%
6662.TWO BioLASCO Taiwan Co., Ltd.
33.00
-0.30%
4192.TWO SynCore Biotechnology Co.,Ltd
33.40
-0.15%
4167.TWO Savior Lifetec Corporation
19.75
-0.25%
6492.TWO Senhwa Biosciences, Inc.
42.35
+0.47%
3176.TWO Medigen Biotechnology Corp.
32.60
-1.21%